The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance?

Author： Rizzo Manfredi   Christ Emanuel R   Rini Giovam Battista   Spinas Giatgen A   Berneis Kaspar  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.13, 2008-09, pp. : 2295-2303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fenofibrate: A Review of its Lipid-Modifying Effects in Dyslipidemia and its Vascular Effects in Type 2 Diabetes Mellitus

By Keating Gillian M.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 4, 2011-08 ,pp. : 227-247

Adis International

Access to resources Recommend Favorite

Beyond Low-Density Lipoprotein: Addressing the Atherogenic Lipid Triad in Type 2 Diabetes Mellitus and the Metabolic Syndrome

By Nesto Richard W.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 6, 2005-01 ,pp. : 379-387

Adis International

Access to resources Recommend Favorite

Alzheimer's Disease and Type 2 Diabetes: What Is the Connection?

By  

The Consultant Pharmacist, Vol. 30, Iss. 2, 2015-02 ,pp. : 112-115

American Society of Consultant Pharmacists

Access to resources Recommend Favorite

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

By Reyes-Soffer Gissette   Rondon-Clavo Carlos   Ginsberg Henry N  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1429-1438

Informa Healthcare

Access to resources Recommend Favorite

PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home

By Billin Andrew N  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1465-1471

Informa Healthcare

Access to resources Recommend Favorite